These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2195868)

  • 1. Specific identification of fibrin(ogen) degradation products in plasma and serum using blotting and peroxidase labeled antiserum.
    Proietti AB; McGuire M; Bell W
    Am J Hematol; 1990 Aug; 34(4):270-4. PubMed ID: 2195868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.
    Connaghan DG; Francis CW; Lane DA; Marder VJ
    Blood; 1985 Mar; 65(3):589-97. PubMed ID: 3971042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction.
    Francis CW; Connaghan DG; Scott WL; Marder VJ
    Circulation; 1987 Jun; 75(6):1170-7. PubMed ID: 3568326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of fibrin(ogen) fragments in gingival crevicular fluid.
    Talonpoika J
    Scand J Dent Res; 1991 Feb; 99(1):40-3. PubMed ID: 2047751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of serum fibrinogen and fibrin fragments produced during disseminated intravascular coagulation.
    Lane DA; Preston FE; VanRoss ME; Kakkar VV
    Br J Haematol; 1978 Dec; 40(4):609-15. PubMed ID: 365218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products.
    Connaghan DG; Francis CW; Ryan DH; Marder VJ
    Am J Clin Pathol; 1986 Sep; 86(3):304-10. PubMed ID: 3751995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of plasma fibrin D-dimer levels with the use of a monoclonal antibody coupled to latex beads.
    Greenberg CS; Devine DV; McCrae KM
    Am J Clin Pathol; 1987 Jan; 87(1):94-100. PubMed ID: 3541576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
    vanDeWater L; Carr JM; Aronson D; McDonagh J
    Blood; 1986 May; 67(5):1468-73. PubMed ID: 2938648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
    Greenberg CS; Achyuthan KE; Rajagopalan S; Pizzo SV
    Arch Biochem Biophys; 1988 Apr; 262(1):142-8. PubMed ID: 2895608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased immunoreactivity of plasma after fibrinolytic activation in an anti-DD ELISA system. Role of soluble crosslinked fibrin polymers.
    Francis CW; Doughney K; Brenner B; Klingbiel K; Marder VJ
    Circulation; 1989 Mar; 79(3):666-73. PubMed ID: 2465100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies.
    Bini A; Mesa-Tejada R; Fenoglio JJ; Kudryk B; Kaplan KL
    Lab Invest; 1989 Jun; 60(6):814-21. PubMed ID: 2659890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrin and fibrinogen proteolysis products: comparison between gel filtration and SDS polyacrylamide electrophoresis analysis.
    Alkjaersig N; Davies A; Fletcher A
    Thromb Haemost; 1977 Aug; 38(2):524-5. PubMed ID: 145666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New strategies in the determination of fibrin and fibrin(ogen) derivatives by monoclonal antibodies.
    Nieuwenhuizen W
    Blut; 1988 Nov; 57(5):285-91. PubMed ID: 3058234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinction between fibrinogen and fibrin degradation products in plasma.
    Gaffney PJ
    Clin Chim Acta; 1975 Nov; 65(1):109-15. PubMed ID: 1192601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New enzyme immunoassay of fibrin-fibrinogen degradation products in plasma using a monoclonal antibody.
    Koopman J; Haverkate F; Koppert P; Nieuwenhuizen W; Brommer EJ; Van der Werf WG
    J Lab Clin Med; 1987 Jan; 109(1):75-84. PubMed ID: 3540164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosslinked fibrin derivatives and fibronectin in ascitic fluid from patients with ovarian cancer compared to ascitic fluid in liver cirrhosis.
    Hafter R; Klaubert W; Gollwitzer R; von Hugo R; Graeff H
    Thromb Res; 1984 Jul; 35(1):53-64. PubMed ID: 6474409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and distribution of fibrinogen, fibrin, and fibrin(ogen) degradation products in atherosclerosis. Use of monoclonal antibodies.
    Bini A; Fenoglio JJ; Mesa-Tejada R; Kudryk B; Kaplan KL
    Arteriosclerosis; 1989; 9(1):109-21. PubMed ID: 2643421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analysis of cross-linked fibrin and fibrinogen degradation products with SDS-PAGE and immunoblot].
    Okumura N; Kagiya H; Kumagai T; Kameko M; Tozuka M; Saito H; Katsuyama T; Kanai M
    Rinsho Byori; 1990 Feb; 38(2):201-7. PubMed ID: 2329722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
    Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
    Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
    Francis CW; Connaghan DG; Marder VJ
    Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.